Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe-Reference-Cited by-同舟云学术

Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe

Published:2018-02-07 Issue:4 Volume:100 Page:367-371
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Geelen Inge G.P.¹^ORCID,Thielen Noortje²³,Janssen Jeroen J.W.M.²,Hoogendoorn Mels⁴,Roosma Tanja J.A.²,Valk Peter J.M.⁵,Visser Otto⁶,Cornelissen Jan J.⁵,Westerweel Peter E.¹

Affiliation:

1. Department of Hematology; Albert Schweitzer Hospital; Dordrecht The Netherlands

2. Department of Hematology; VU University Medical Center; Amsterdam The Netherlands

3. Department of Internal Medicine; Diakonessenhuis; Utrecht The Netherlands

4. Department of Hematology; Medical Center Leeuwarden; Leeuwarden The Netherlands

5. Department of Hematology; Erasmus University Medical Center; Rotterdam The Netherlands

6. Netherlands Comprehensive Cancer Organisation (IKNL); Utrecht The Netherlands

Funder

Novartis

Bristol-Myers Squibb

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.13023/fullpdf

Reference15 articles.

1. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib;Goldberg;Curr Med Res Opin,2013

2. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting;Saleh;Curr Med Res Opin,2014

3. Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival;Geelen;Haematologica,2017

4. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

5. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression;Marktel;Haematologica,2003

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population;Haematologica;2023-03-23

2. Current Guidelines and Treatment Algorithm of Chronic Myeloid Leukemia;Pathogenesis and Treatment of Leukemia;2023

3. The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era;Haematologica;2022-03-31

4. Epidemiology of Chronic Myeloid Leukaemia;Hematologic Malignancies;2021

5. Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice;HemaSphere;2020-11-24